Passage BIO PASG
NASDAQ PASG
$3.51 -0.08 (-2.23%)
At close: Oct 22, 2026 · 4:00 PM EDT

Passage BIO (PASG) Preferred Stock Liabilities (2019)

Updated

Passage BIO (PASG) recorded Preferred Stock Liabilities of $230.61 million in Q4 2019, up 109.8% from the prior quarter.

Analysis

Passage BIO (PASG) Preferred Stock Liabilities (2019) Analysis & Trends

Starting with Q1 2019, Passage BIO's Preferred Stock Liabilities history includes 4 quarters.

  • Per Business Quant, the preceding three quarters came in at $109.9 million (Q3 2019), $74.4 million (Q2 2019) and $63.1 million (Q1 2019).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn -
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn -
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 Passage BIO 11.46 Mn -145.16 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 230.61 Mn
Sep 30, 2019 109.90 Mn
Jun 30, 2019 74.40 Mn
Mar 31, 2019 63.10 Mn
API Access

Passage BIO Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=PASG&period=max&api_key=YOUR_API_KEY